Physician profile
Mark Peter Nespeca
NPI 1942371703
$4,288.73
in general payments reported to CMS, 2019-2025
21 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,608 · 2020: $494 · 2021: $235 · 2022: $306 · 2023: $50.84 · 2024: $437 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $891.67 | 2019-2022 | |
| Livanova USA, INC. | $624.73 | 2019-2020 | |
| Greenwich Biosciences, INC. | $457.37 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $424.54 | 2022-2025 | Epidiolex |
| Mallinckrodt Enterprises LLC | $399.89 | 2019 | |
| Neurelis, INC. | $350.56 | 2021-2025 | Valtoco |
| Ucb, INC. | $236.38 | 2019-2025 | Fintepla |
| Supernus Pharmaceuticals, INC. | $180.36 | 2019 | |
| Biomarin Pharmaceutical INC. | $151.67 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $84.05 | 2019-2025 | |
| Eisai INC. | $79.16 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $72.25 | 2019 | |
| Csl Behring | $62.80 | 2019-2020 | |
| Travere Therapeutics, INC. | $52.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.76 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $50.24 | 2020 | |
| Neuropace, INC. | $35.51 | 2020-2021 | |
| Zogenix INC. | $22.33 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $22.31 | 2024 | |
| Immedica Pharma US, INC. | $21.75 | 2024 | |
| Biocodex, INC. | $16.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nespeca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.